BCLI insider transaction filings
BRAINSTORM CELL THERAPEUTICS INC. — 13 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-28. Screen BCLI transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-28 | 4 | FRENKEL JACOB A — Director | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-07-28 | 4 | Pitts Peter Joe — Executive Chairman, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Lebovits Chaim — President & CEO | Grant/award (A): 1,800,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | Yablonka Uri — EVP & Chief Business Officer, Director | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | Patlis Alla — See Remarks | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | FRENKEL JACOB A — Director | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | ARBEL IRIT — Director | Grant/award (A): 120,000 @ $0 | EDGAR |
| 2026-05-20 | 4 | Bairu Menghisteab — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Polverino Anthony J. — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | HARTOUNIAN HARTOUN — Director | Grant/award (A): 225,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Lindborg Stacy — Director | Grant/award (A): 150,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Naor Nir — Director | Grant/award (A): 180,000 (derivative) @ $0.70 | EDGAR |
| 2026-05-20 | 4 | Dagher Ibrahim B. — Director | Grant/award (A): 225,000 (derivative) @ $0.70 | EDGAR |
Recent 8-K events — BRAINSTORM CELL THERAPEUTICS INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BCLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →